Insider Buying: Medifast (NYSE:MED) Director Buys $529,019.00 in Stock

Medifast Inc (NYSE:MED) Director Parsa Kiai acquired 43,150 shares of the company’s stock in a transaction dated Wednesday, August 26th. The stock was acquired at an average cost of $12.26 per share, for a total transaction of $529,019.00. Following the completion of the purchase, the director directly owned 707,492 shares in the company, valued at $8,673,851.92. This trade represents a 6.50% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Parsa Kiai also recently made the following trade(s):

• On Monday, August 24th, Parsa Kiai bought 4,329 shares of Medifast stock. The shares were acquired at an average price of $12.00 per share, for a total transaction of $51,948.00.
• On Thursday, August 20th, Parsa Kiai bought 43,150 shares of Medifast stock. The shares were acquired at an average cost of $11.60 per share, with a total value of $500,540.00.
• On Wednesday, August 19th, Parsa Kiai bought 29,337 shares of Medifast stock. The stock was acquired at an average price of $11.66 per share, with a total value of $342,069.42.

Medifast Stock Performance

Shares of MED opened at $12.17 on Monday. The firm has a market cap of $136.06 million, a PE ratio of -5.22 and a beta of 0.65. Medifast Inc has a 52-week low of $9.22 and a 52-week high of $14.67. The business’s 50 day moving average price is $11.00 and its two-hundred day moving average price is $11.10.

Medifast (NYSE:MED) last announced its quarterly earnings data on Monday, August 3rd. The specialty retailer reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.37. The company had revenue of $76.38 million during the quarter, compared to the consensus estimate of $72.70 million. Medifast had a negative net margin of 8.08% and a negative return on equity of 6.69%. Medifast has set its FY 2026 guidance at -1.750–0.250 EPS and its Q3 2026 guidance at -0.650–0.150 EPS. Research analysts predict that Medifast Inc will post -1.04 EPS for the current fiscal year.

Institutional Investors Weigh In On Medifast

Several hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets lifted its holdings in shares of Medifast by 103.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock worth $32,000 after purchasing an additional 1,187 shares in the last quarter. Quantbot Technologies LP bought a new stake in Medifast during the 3rd quarter valued at $37,000. Intesa Sanpaolo Wealth Management bought a new stake in Medifast during the 4th quarter valued at $47,000. State of Wyoming acquired a new position in Medifast during the fourth quarter worth $59,000. Finally, Ancora Advisors LLC acquired a new position in Medifast during the second quarter worth $75,000. Institutional investors own 95.51% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on MED shares. Zacks Research downgraded shares of Medifast from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 11th. Weiss Ratings raised shares of Medifast from a “sell (e+)” rating to a “sell (d)” rating in a research report on Monday, August 17th. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus target price of $12.00.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.